Papers: 2013
-
Quantification of endocannabinoids in postmortem brain of schizophrenic subjects Schizophrenia Research, 2013; 148 (1), 145 - 150
-
Antidepressant-like properties of three new α2-adrenoceptor antagonists Neuropharmacology, 2013; 65, 13 - 19
-
Analysis of Sp transcription factors in the postmortem brain of chronic schizophrenia: a pilot study of relationship to negative symptoms Journal of Psychiatric Research, 2013; 47, 926 - 934
-
Description of a bivalent cannabinoid ligand with hypophagic properties Archiv Der Pharmazie, 2013; 346, 171 - 179
-
Behavioral, neurochemical and morphological changes induced by the overexpression of munc18-1a in brain of mice: relevance to schizophrenia Translational Psychiatry 3:e221, 2013
-
Brain RGS4 and RGS10 protein expression in schizophrenia and depression. Effect of drug treatment Psychopharmacology, 2013; 226, 177 - 188
-
Cyclin-dependent kinase-5 and p35/p25 activators in schizophrenia and major depression prefrontal cortex: basal contents and effects of psychotropic medications International Journal of Neuropsychopharmacology, 2013; 16, 683 - 689
-
Additive effect of rimonabant and citalopram on extracellular serotonin levels monitored with in vivo microdialysis in rat brain European Journal of Pharmacology, 2013; 709, 13 - 19
-
Involvement of serotonin 5-HT3 receptors in the modulation of noradrenergic transmission by serotonin reuptake inhibitors: a microdialysis study in rat brain Psychopharmacology, 2013; 229, 331 - 344
-
Dysregulated 5-HT(2A) receptor binding in postmortem frontal cortex of schizophrenic subjects European Neuropsychopharmacology, 2013; 23, 852 - 864
-
Chronic pain leads to concomitant noradrenergic impairment and mood disorders Biological Psychiatry, 2013; 73, 54 - 62